Inclusion Criteria:  18 years of age or older pathology-confirmed diagnosis of RCC at least one tumor lesion greater than 1 cm in diameter (in primary kidney site and/or in a metastatic site such as liver or adrenal gland), amenable to ultrasound imaging planned to be treated with ipilimumab plus nivolumab or other ICI written informed consent  Exclusion Criteria:  any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study (e.g., compromised consent capacity) hypersensitivity to sulfur hexafluoride lipid microsphere or its components, such as polyethylene glycol (PEG)